Latest News



BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting. Link to Press Release

Results of BMX-HGG Study: A multi-institutional, randomized, Phase 2 clinical trial of concurrent chemoradiation with or without BMX-001 in patients with newly diagnosed high grade glioma. Peters et al. SNO 2023. Link to abstract.

BioMimetix Announces Acceptance of Late-Breaking Abstract and Oral Presentation of BMX-001 Clinical Data at the 2023 Society for Neuro-Oncology Annual Meeting. Link to Press Release


BioMimetix launches randomized Phase 2 clinical trial studying BMX-010 ointment in adults with Atopic Dermatitis.


Breakthrough Therapy designation awarded for BMX-001 to be used in combination with standard radiotherapy and temozolomide for newly diagnosed high-grade glioma.


MASCC Conference moved to June 2021, BMX-001 High grade glioma abstract accepted, Title: Cognitive Outcomes Of Phase 1 Trial Of Novel Metalloporphyrin Radioprotectant And Radiosensitizer In Newly Diagnosed High Grade Glioma Patients.


A Phase 1-2 Trial of Concurrent Radiation Therapy, Cisplatin and BMX-001 in Locally Advanced Head and Neck Cancer.  Brizel DM at al.  ASTRO 2021 Link to abstract.

The Phase I Results of A Phase 1/2 Trial for Patients with Newly Diagnosed Anal
Cancer Treated with Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001.  Lin C et al.  ASTRO 2021 Link to abstract.

Clinical Trials in Progress:  BMX-HGG: Phase 2 Trial of Newly Diagnosed High-Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001.  Peters et al.  ASCO 2021.  Link to abstract.


Preserving Neurocognition without Compromising Tumor Control during Whole-Brain Radiotherapy Therapy in Patients with Numerous Brain Metastases via a Novel Superoxide Dismutase Mimetic: Initial Safety Lead-In and Design of a Clinical Trial.  Kirkpatrick J et al.  ASTRO 2020.  Link to abstract.

June 2020

Link to ASCO 2020 Abstract for Clinical Trials In Progress, BMX-001 in patients with HGG:

May 2020

BioMimetix is awarded a Phase IIb bridge award from the National Cancer Institute to support ongoing Phase 2 randomized trial studying BMX-001 in combination with Temozolomide and Radiation Therapy in patients with High Grade Glioma,

May 2020

BioMimetix announces they received Fast Track Designation for the investigation of BMX-001 in combination with RT and TMZ for the treatment of patients with newly diagnosed high grade glioma to demonstrate a clinically meaningful and statistically robust improvement in overall

Fast Track is a process designed to promote the development and speed up the review of drugs for serious conditions with an unmet medical need. This helps lead to faster availability of new treatment options for patients.

BMX-001 is currently being studied in a randomized Phase 2 trial of HGG patients receiving radiation therapy and temozolomide.

January 2020

BioMimetix’s novel drug, BMX-001, is granted Orphan Designation by the FDA for treatment of glioma

June 2019

BioMimetix was selected by the NIH to showcase in the Innovation Zone at BIO International Convention in Philadelphia, PA,  June 3-6, 2019.

January 2019

BioMimetix awarded grant by the National Institutes of Health to fund work in patients with Multiple Brain Metastases.

Share This Webpage

Share this page with your friends!